You are here

Article Text

Article menu
Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
Teriparatide treatment complicated by malignant myeloma
  1. Anna-Mari Koski1,
  2. Anu Sikiö2,
  3. Terje Forslund3
  1. 1Division of Endocrinology, Department of Medicine, Central Finland Health Care District Hospital Jyväskylä, Jyväskylä, Finland
  2. 2Division of Haematology, Department of Medicine, Central Finland Health Care District Hospital Jyväskylä, Jyväskylä, Finland
  3. 3Division of Nephrology, Department of Medicine, Central Finland Health Care District Hospital Jyväskylä, Jyväskylä, Finland
  1. Correspondence to Terje Forslund, terje.forslund{at}ksshp.fi

Summary

Recombinant human parathyroid hormone (1–34) (rhPTH 1–34), teriparatide (Forsteo in Europe), is a new compound that has been introduced and shown to be successful in the treatment of osteoporosis. The mechanisms of action include a pulsative influence on the RANKL/OPG system resulting in osteoblast activation and increased bone formation by teriparatide. In malignant myeloma there is an imbalance between osteoclast and osteoblast activity with involvement of the RANKL/OPG system among others. We report a case with monoclonal gammopathy of uncertain significance (MGUS) who developed malignant myeloma after teriparatide treatment and we suggest that in addition to malignant myeloma and smouldering myeloma, MGUS should also be considered contraindicated for teriparatide treatment.

https://doi.org/10.1136/bcr.01.2010.2681

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Competing interests Dr Anna-Mari Koski has received a travelling grant in order to attend an European Meeting on Treatment of Osteoporosis in October 2009.

    • Patient consent Obtained.